Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500885 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2NOS1GAAESR2HSD17B10 | |
| SCHEMBL24919807 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2NOS1ESR2HSD17B10L3MBTL1 | |
| SCHEMBL3549501 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2NOS1GAAESR2HSD17B10 | |
| SCHEMBL26350953 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2NOS1GAAESR2HSD17B10 | |
| SCHEMBL22222465 | 0.76 | KDM4E (0.41) | KDM4EL3MBTL1ADORA2ANPC1MAPT | |
| SCHEMBL28015932 | 0.75 | ESR2 (0.31) | ESR2HSD17B10L3MBTL1POLB | |
| SCHEMBL21011913 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2NOS1GAAESR2HSD17B10 | |
| SCHEMBL22692419 | 0.72 | ATP4A (0.33) | KDM4ESMN1; SMN2MAPTHTTRAB9A | |
| SCHEMBL10192297 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2NOS1GAAESR2HSD17B10 | |
| SCHEMBL13103844 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2NOS1GAAESR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | KDM4E 4243/4885SMN1; SMN2 1424/4885NOS1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.